{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:03:48Z","timestamp":1794549828415,"version":"4.9.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["853966"],"award-info":[{"award-number":["853966"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined. In the present document we used a Delphi-method-based consensus approach to define TRD and PRD and to serve as operational criteria for future clinical studies, especially if conducted for regulatory purposes. We reviewed the literature and brought together a group of international experts (including clinicians, academics, researchers, employees of pharmaceutical companies, regulatory bodies representatives, and one person with lived experience) to evaluate the state-of-the-art and main controversies regarding the current classification. We then provided recommendations on how to design clinical trials, and on how to guide research in unmet needs and knowledge gaps. This report will feed into one of the main objectives of the EUropean Patient-cEntric clinicAl tRial pLatforms, Innovative Medicines Initiative (EU-PEARL, IMI) MDD project, to design a protocol for platform trials of new medications for TRD\/PRD.<\/jats:p>","DOI":"10.1038\/s41380-021-01381-x","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T21:02:39Z","timestamp":1639515759000},"page":"1286-1299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-0391","authenticated-orcid":false,"given":"Luca","family":"Sforzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0539-2376","authenticated-orcid":false,"given":"Courtney","family":"Worrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Kose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Aouizerate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Arolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-859X","authenticated-orcid":false,"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard T.","family":"Baune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6990-939X","authenticated-orcid":false,"given":"Anthony J.","family":"Cleare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-6138","authenticated-orcid":false,"given":"Philip J.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2316-7220","authenticated-orcid":false,"given":"Timothy G.","family":"Dinan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Nicol","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Hegerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-781X","authenticated-orcid":false,"given":"Andrew D.","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5473-3697","authenticated-orcid":false,"given":"Marion","family":"Leboyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Hamish","family":"McAllister-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meyer-Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-7997","authenticated-orcid":false,"given":"Andrew H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7867-1160","authenticated-orcid":false,"given":"Charles B.","family":"Nemeroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5693-8936","authenticated-orcid":false,"given":"Claus","family":"Normann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1401","authenticated-orcid":false,"given":"David","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pallanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W. J. H.","family":"Penninx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"Schatzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi N.","family":"Yatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":false,"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Aislaitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Butlen-Ducuing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Haberkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Laughren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni-Laura","family":"M\u00e4ntyl\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Schruers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gara","family":"Arteaga-Henr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-856X","authenticated-orcid":false,"given":"Francesco","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Cash-Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-8333","authenticated-orcid":false,"given":"Woo Ri","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-4799","authenticated-orcid":false,"given":"Stefan M.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witte J. G.","family":"Hoogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Jord\u00e1n","family":"Mondrag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Martynowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Melloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-997X","authenticated-orcid":false,"given":"Christian","family":"Otte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Perez-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-0246","authenticated-orcid":false,"given":"Sara","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-3549","authenticated-orcid":false,"given":"Edwin","family":"van de Ketterij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Flossbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1622-0350","authenticated-orcid":false,"given":"J. Antoni","family":"Ramos-Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Savitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9132-5091","authenticated-orcid":false,"given":"Carmine M.","family":"Pariante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357\u201366.","journal-title":"Lancet"},{"key":"1381_CR2","doi-asserted-by":"crossref","unstructured":"Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Nature disease primer: Major Depressive Disorder. Nature Publishing Group. 2016.","DOI":"10.1038\/nrdp.2016.65"},{"key":"1381_CR3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"1381_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","volume":"156","author":"RS McIntyre","year":"2014","unstructured":"McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, et al. Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1\u20137.","journal-title":"J Affect Disord"},{"key":"1381_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/da.22968","volume":"37","author":"BN Gaynes","year":"2019","unstructured":"Gaynes BN, Lux L, Gartlehner G, Asher G, Forman\u2010Hoffman V, Green J, et al. Defining treatment\u2010resistant depression. Depression Anxiety. 2019;37:134\u201345.","journal-title":"Depression Anxiety"},{"key":"1381_CR6","doi-asserted-by":"crossref","unstructured":"Salloum NC, Papakostas GI. Staging treatment intensity and defining resistant depression: Historical overview and future directions. Journal of Clinical Psychiatry. 2019, 80.","DOI":"10.4088\/JCP.18r12250"},{"key":"1381_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","volume":"267","author":"RH McAllister-Williams","year":"2020","unstructured":"McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. The identification, assessment and management of difficult-to-treat depression: An international consensus statement. J Affect Disord. 2020;267:264\u201382.","journal-title":"J Affect Disord"},{"key":"1381_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/YIC.0b013e328341bb5f","volume":"26","author":"DV Sheehan","year":"2011","unstructured":"Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol. 2011;26:75\u201383. Mar.","journal-title":"Int Clin Psychopharmacol"},{"key":"1381_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1192\/bjp.2017.33","volume":"212","author":"RH McAllister-Williams","year":"2018","unstructured":"McAllister-Williams RH, Christmas DMB, Cleare AJ, Currie A, Gledhill J, Insole L, et al. Multiple-therapy-resistant major depressive disorder: A clinically important concept. Br J Psychiatry. 2018;212:274\u20138.","journal-title":"Br J Psychiatry"},{"key":"1381_CR10","doi-asserted-by":"crossref","unstructured":"Fekadu A, Donocik JG, Cleare AJ. Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry. 2018, 18.","DOI":"10.1186\/s12888-018-1679-x"},{"key":"1381_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","volume":"74","author":"CR Conway","year":"2017","unstructured":"Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: When Enough is enough. JAMA Psychiatry Am Med Assoc. 2017;74:9\u201310.","journal-title":"JAMA Psychiatry Am Med Assoc"},{"key":"1381_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/0706743719828965","volume":"64","author":"S Brown","year":"2019","unstructured":"Brown S, Rittenbach K, Cheung S, McKean G, MacMaster FP, Clement F. Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews. Can J Psychiatry SAGE Publ Inc. 2019;64:380\u20137.","journal-title":"Can J Psychiatry SAGE Publ Inc"},{"key":"1381_CR13","first-page":"1","volume":"13","author":"OD Howes","year":"2021","unstructured":"Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry 2021. 2021;13:1\u201315. Jul.","journal-title":"Mol Psychiatry 2021"},{"key":"1381_CR14","doi-asserted-by":"crossref","unstructured":"Taylor RW, Marwood L, Oprea E, Deangel V, Mather S, Valentini B, et al. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. International Journal of Neuropsychopharmacology. 2021.","DOI":"10.1093\/ijnp\/pyaa033"},{"key":"1381_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1192\/bjp.2018.291","volume":"214","author":"R Strawbridge","year":"2019","unstructured":"Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, et al. Augmentation therapies for treatment-resistant depression: Systematic review and meta-analysis. Br J Psychiatry. 2019;214:308\u2013308.","journal-title":"Br J Psychiatry"},{"key":"1381_CR16","first-page":"14","volume":"8","author":"RH McAllister-Williams","year":"2021","unstructured":"McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. Reconceptualising treatment-resistant depression as difficult-to-treat depression. The Lancet. Psychiatry 2021;8:14\u201315.","journal-title":"Psychiatry"},{"key":"1381_CR17","doi-asserted-by":"publisher","first-page":"e1000217","DOI":"10.1371\/journal.pmed.1000217","volume":"7","author":"D Moher","year":"2010","unstructured":"Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7:e1000217.","journal-title":"PLoS Med"},{"key":"1381_CR18","first-page":"11","volume":"8","author":"L Cosgrove","year":"2021","unstructured":"Cosgrove L, Naudet F, H\u00f6gberg G, Shaughnessy AF, Cristea IA. Reconceptualising treatment-resistant depression as difficult-to-treat depression. The Lancet. Psychiatry 2021;8:11\u20133.","journal-title":"Psychiatry"},{"key":"1381_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jclinepi.2018.10.011","volume":"106","author":"S Humphrey-Murto","year":"2019","unstructured":"Humphrey-Murto S, de Wit M. The Delphi method\u2014more research please. J Clin Epidemiol Elsevier USA. 2019;106:136\u20139.","journal-title":"J Clin Epidemiol Elsevier USA"},{"key":"1381_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jclinepi.2018.03.007","volume":"99","author":"S Grant","year":"2018","unstructured":"Grant S, Booth M, Khodyakov D. Lack of preregistered analysis plans allows unacceptable data mining for and selective reporting of consensus in Delphi studies. J Clin Epidemiol. 2018;99:96\u2013105. Jul 1.","journal-title":"J Clin Epidemiol"},{"key":"1381_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401\u20139. Apr.","journal-title":"J Clin Epidemiol"},{"key":"1381_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","volume":"53","author":"M Fava","year":"2003","unstructured":"Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649\u201359.","journal-title":"Biol Psychiatry"},{"key":"1381_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4088\/JCP.v63n0913","volume":"63","author":"RMA Hirschfeld","year":"2002","unstructured":"Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al. Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. J Clin Psychiatry. 2002;63:826\u201337.","journal-title":"J Clin Psychiatry"},{"key":"1381_CR24","doi-asserted-by":"crossref","unstructured":"Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Canadian Journal of Psychiatry. 2016.","DOI":"10.1177\/0706743716659417"},{"key":"1381_CR25","doi-asserted-by":"crossref","unstructured":"Jackson WC, Papakostas GI, Rafeyan R, Trivedi MH. Recognizing Inadequate Response in Patients With Major Depressive Disorder. The Journal of clinical psychiatry. 2020, 81.","DOI":"10.4088\/JCP.OT19037BR2"},{"key":"1381_CR26","unstructured":"Food and Drug Administration. Major Depressive Disorder: Developing Drugs for Treatment, Guidance for Industry\u2019, DRAFT GUIDANCE. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Revision 1. 2018."},{"key":"1381_CR27","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression. EMA\/CHMP\/185423\/2010 Rev 2. 2013."},{"key":"1381_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-017-0417-0","volume":"31","author":"KR Keyloun","year":"2017","unstructured":"Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017;31:421\u201332.","journal-title":"CNS Drugs"},{"key":"1381_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jad.2008.07.011","volume":"115","author":"MC ten Doesschate","year":"2009","unstructured":"ten Doesschate MC, Bockting CLH, Schene AH. Adherence to continuation and maintenance antidepressant use in recurrent depression. J Affect Disord. 2009;115:167\u201370.","journal-title":"J Affect Disord"},{"key":"1381_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2015.12.029","volume":"193","author":"SC Ho","year":"2016","unstructured":"Ho SC, Chong HY, Chaiyakunapruk N, Tangiisuran B, Jacob SA. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review. J Affect Disord. 2016;193:1\u201310.","journal-title":"J Affect Disord"},{"key":"1381_CR31","doi-asserted-by":"publisher","first-page":"pyw066","DOI":"10.1093\/ijnp\/pyw066","volume":"19","author":"A Frazer","year":"2016","unstructured":"Frazer A, Blier P. A Neuroscience-based Nomenclature (NbN) for psychotropic agents. Int J Neuropsychopharmacol. 2016;19:pyw066.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1381_CR32","first-page":"459","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015. 2015;29:459\u2013525.","journal-title":"J Psychopharmacol 2015"},{"key":"1381_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/acps.13145","volume":"141","author":"TA Furukawa","year":"2020","unstructured":"Furukawa TA, Salanti G, Cowen PJ, Leucht S, Cipriani A. No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. Acta Psychiatr Scandinavica. 2020;141:401\u20139.","journal-title":"Acta Psychiatr Scandinavica"},{"key":"1381_CR34","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1038\/tp.2016.104","volume":"6","author":"F Hieronymus","year":"2016","unstructured":"Hieronymus F, Nilsson S, Eriksson E. A mega-Analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry. 2016;6:e834\u2013e834.","journal-title":"Transl Psychiatry"},{"key":"1381_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1176\/appi.ajp.2015.15030331","volume":"173","author":"E Jakubovski","year":"2016","unstructured":"Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic review and meta-analysis: Dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry. 2016;173:174\u201383.","journal-title":"Am J Psychiatry"},{"key":"1381_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3109\/15622970701432528","volume":"11","author":"GI Papakostas","year":"2010","unstructured":"Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2010;11:300\u20137.","journal-title":"World J Biol Psychiatry"},{"key":"1381_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4088\/JCP.07m03780","volume":"70","author":"A Szegedi","year":"2009","unstructured":"Szegedi A, Jansen WT, Van Willigenburg APP, Van Der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344\u201353.","journal-title":"J Clin Psychiatry"},{"key":"1381_CR38","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/da.22832","volume":"35","author":"ME Kelley","year":"2018","unstructured":"Kelley ME, Dunlop BW, Nemeroff CB, Lori A, Carrillo-Roa T, Binder EB, et al. Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. Depression Anxiety. 2018;35:992\u20131000.","journal-title":"Depression Anxiety"},{"key":"1381_CR39","first-page":"28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D. Implic Clin Pract. 2006;163:28\u201340. Jan 1.","journal-title":"Implic Clin Pract"},{"key":"1381_CR40","first-page":"383","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant. Depression: Int Expert Opin Available Evid Implement. 2021;178:383\u201399. Mar 17.","journal-title":"Depression: Int Expert Opin Available Evid Implement"},{"key":"1381_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0716-y","volume":"10","author":"MF Pradier","year":"2020","unstructured":"Pradier MF, McCoy TH, Hughes M, Perlis RH, Doshi-Velez F. Predicting treatment dropout after antidepressant initiation. Transl Psychiatry. 2020;10:60.","journal-title":"Transl Psychiatry"},{"key":"1381_CR42","doi-asserted-by":"crossref","unstructured":"Bauer M, Severus E, K\u00f6hler S, Whybrow PC, Angst J, M\u00f6ller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: Maintenance treatment of major depressive disorder-update 2015. World Journal of Biological Psychiatry. 2015.","DOI":"10.3109\/15622975.2014.1001786"},{"key":"1381_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/mp.2018.2","volume":"23","author":"MP Dandekar","year":"2018","unstructured":"Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J. Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications. Mol Psychiatry. 2018;23:5. 2018 Feb 27;23:1094\u2013112.","journal-title":"Mol Psychiatry"},{"key":"1381_CR44","first-page":"839","volume":"4","author":"PE Holtzheimer","year":"2017","unstructured":"Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA, McClintock S, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. The Lancet. Psychiatry 2017;4:839\u201349.","journal-title":"Psychiatry"},{"key":"1381_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.expneurol.2009.04.015","volume":"219","author":"AJ Rush","year":"2009","unstructured":"Rush AJ, Siefert SE. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Exp Neurol. 2009;219:36\u201343.","journal-title":"Exp Neurol"},{"key":"1381_CR46","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","volume":"68","author":"D Souery","year":"2007","unstructured":"Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. J Clin Psychiatry. 2007;68:1062\u201370.","journal-title":"J Clin Psychiatry"},{"key":"1381_CR47","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archpsyc.65.8.870","volume":"65","author":"AJ Rush","year":"2008","unstructured":"Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, et al. Selecting among second-step antidepressant medication monotherapies: Predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65:870\u201380.","journal-title":"Arch Gen Psychiatry"},{"key":"1381_CR48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","volume":"20","author":"L Bartova","year":"2019","unstructured":"Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, et al. Results of the European Group for the Study of Resistant Depression (GSRD) \u2014 basis for further research and clinical practice. World J Biol Psychiatry. 2019;20:427\u201348.","journal-title":"World J Biol Psychiatry"},{"key":"1381_CR49","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/0004867419835933","volume":"53","author":"TA Braund","year":"2019","unstructured":"Braund TA, Palmer DM, Williams LM, Harris AWF. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report. Aust NZ J Psychiatry. 2019;53:782\u201393.","journal-title":"Aust NZ J Psychiatry"},{"key":"1381_CR50","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1177\/0269881113499205","volume":"27","author":"MF Juruena","year":"2013","unstructured":"Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. The role of mineralocorticoid receptor function in treatment-resistant depression. J Psychopharmacol. 2013;27:1169\u201379.","journal-title":"J Psychopharmacol"},{"key":"1381_CR51","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","volume":"25","author":"R Strawbridge","year":"2015","unstructured":"Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015;25:1532\u201343.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1381_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1176\/appi.ajp.2016.15111500","volume":"174","author":"LA Pan","year":"2017","unstructured":"Pan LA, Martin P, Zimmer T, Segreti AM, Kassiff S, McKain BW, et al. Neurometabolic disorders: Potentially treatable abnormalities in patients with treatment-refractory depression and suicidal behavior. Am J Psychiatry. 2017;174:42\u201350.","journal-title":"Am J Psychiatry"},{"key":"1381_CR53","unstructured":"First, MB, Spitzer, RL, Gibbon M, and Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders. New York State Psychiatric Institute. 2002."},{"key":"1381_CR54","unstructured":"First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 research version. American Psychiatric Association, Washington DC. 2015."},{"key":"1381_CR55","doi-asserted-by":"crossref","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. In: Journal of Clinical Psychiatry. 1998.","DOI":"10.1037\/t18597-000"},{"key":"1381_CR56","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1755-5949.2009.00102.x","volume":"16","author":"GM Chandler","year":"2010","unstructured":"Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. Validation of the massachusetts general hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Therapeutics. 2010;16:322\u20135.","journal-title":"CNS Neurosci Therapeutics"},{"key":"1381_CR57","first-page":"10","volume":"62","author":"HA Sackeim","year":"2001","unstructured":"Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62:10\u20137. Suppl 16.","journal-title":"J Clin Psychiatry"},{"key":"1381_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jad.2011.02.020","volume":"137","author":"HG Ruh\u00e9","year":"2012","unstructured":"Ruh\u00e9 HG, Van Rooijen G, Spijker J. Peeters FPML, Schene AH. Staging methods for treatment resistant depression. A systematic review. J Affect Disord. 2012;137:35\u201345.","journal-title":"J Affect Disord"},{"key":"1381_CR59","unstructured":"Thase ME, Rush AJ. When at first you don\u2019t succeed: Sequential strategies for antidepressant nonresponders. In: Journal of Clinical Psychiatry. 1997."},{"key":"1381_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4088\/JCP.08m04309","volume":"70","author":"A Fekadu","year":"2009","unstructured":"Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, et al. A multidimensional tool to quantify treatment resistance in depression: The Maudsley staging method. J Clin Psychiatry. 2009;70:177\u201384.","journal-title":"J Clin Psychiatry"},{"key":"1381_CR61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol, Neurosurg, psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol, Neurosurg, psychiatry"},{"key":"1381_CR62","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"1381_CR63","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573\u201383.","journal-title":"Biol Psychiatry"},{"key":"1381_CR64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for Measuring Depression. Arch Gen Psychiatry. 1961;4:561\u201371.","journal-title":"Arch Gen Psychiatry"},{"key":"1381_CR65","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"key":"1381_CR66","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","volume":"48","author":"E Frank","year":"1991","unstructured":"Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851\u20135.","journal-title":"Arch Gen Psychiatry"},{"key":"1381_CR67","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0165-0327(01)00451-7","volume":"72","author":"CJ Hawley","year":"2002","unstructured":"Hawley CJ, Gale TM, Sivakumaran T. Defining remission by cut off score on the MADRS: Selecting the optimal value. J Affect Disord. 2002;72:177\u201384.","journal-title":"J Affect Disord"},{"key":"1381_CR68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4088\/JCP.v65n0204","volume":"65","author":"M Zimmerman","year":"2004","unstructured":"Zimmerman M, Posternak MA, Chelminski I. Defining remission on the montgomery-asberg depression rating scale. J Clin Psychiatry. 2004;65:163\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1381_CR69","doi-asserted-by":"crossref","unstructured":"Guy W. Rating Clinician-rated | Clinical Global Impression (CGI). ECDEU Assessment Manual for Psychopharmacology. 1976.","DOI":"10.1037\/e591322011-001"},{"key":"1381_CR70","first-page":"93","volume":"27","author":"AC Leon","year":"1997","unstructured":"Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assess Psychiatr Impairment Prim Care Sheehan Disabil Scale. 1997;27:93\u2013105. Jul 1.","journal-title":"Assess Psychiatr Impairment Prim Care Sheehan Disabil Scale"},{"key":"1381_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/2229-3485.86879","volume":"2","author":"P Deshpande","year":"2011","unstructured":"Deshpande P, Bl Sudeepthi, Rajan S, Abdul Nazir C. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2:137\u201344.","journal-title":"Perspect Clin Res"},{"key":"1381_CR72","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"1381_CR73","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1176\/appi.ajp.161.12.2163","volume":"161","author":"RM Bagby","year":"2004","unstructured":"Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: Has the gold standard become a lead weight? Am J Psychiatry Am Psychiatr Publ. 2004;161:2163\u201377.","journal-title":"Am J Psychiatry Am Psychiatr Publ"},{"key":"1381_CR74","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1017\/S0033291707001730","volume":"38","author":"R Uher","year":"2008","unstructured":"Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, et al. Measuring depression: Comparison and integration of three scales in the GENDEP study. Psychological Med. 2008;38:289\u2013300. Feb.","journal-title":"Psychological Med"},{"key":"1381_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"MH Trivedi","year":"2004","unstructured":"Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Med. 2004;34:73\u201382. Jan.","journal-title":"Psychological Med"},{"key":"1381_CR76","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1017\/S1092852914000406","volume":"19","author":"P Pedrelli","year":"2014","unstructured":"Pedrelli P, Blais MA, Alpert JE, Shelton RC, Walker RSW, Fava M. Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). CNS Spectr. 2014;19:535\u201346. Dec 23.","journal-title":"CNS Spectr"},{"key":"1381_CR77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u20135.","journal-title":"Br J Med Psychol"},{"key":"1381_CR78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpsychires.2010.04.032","volume":"45","author":"BW Dunlop","year":"2011","unstructured":"Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, et al. Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. J Psychiatr Res. 2011;45:96\u2013103.","journal-title":"J Psychiatr Res"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01381-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T23:40:42Z","timestamp":1652312442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01381-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1038\/s41380-021-01381-x","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"assertion":[{"value":"29 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LS reports grant from European Commission (IMI2 853966), during the conduct of the study. CW reports grant from European Commission (IMI2 853966), during the conduct of the study. MK reports grant from European Commission (IMI2 853966), during the conduct of the study. IMA has nothing to disclose. BA reports personal fees from Lundbeck, personal fees and non-financial support from Janssen-Cilag, personal fees from Sanofi, personal fees from Eli Lilly, outside the submitted work; and has served on the advisory board of Janssen-Cilag. VA reports personal fees from Astra-Zeneca, personal fees from Gilead Sciences, personal fees from Janssen, personal fees from Lundbeck, personal fees from Neuraxpharm, personal fees from Otsuka, personal fees from Sanofi\/Genzyme, personal fees from Servier, grants from European Union- Horizon 2020, grants from Medical Faculty Muenster- Interdisciplinary Center for Clinical Research, outside the submitted work; and Has served on Advisory Boards for Allergan, Astra-Zeneca, Janssen, Lundbeck, Neuraxpharm, Otsuka, Sanofi\/Genzyme, Servier and Trommsdorff. MB reports grants from Deutsche Forschungsgemeinschaft (DFG), grants from European Commission, grants from Bundesministerium f\u00fcr Bildung und Forschung (BMBF), personal fees from Aristo, personal fees from GH Research, personal fees from Hexal, personal fees from Janssen, personal fees from Janssen-Cilag, personal fees from Neuraxpharm, personal fees from Novartis, personal fees from Sandoz, personal fees from Shire International, personal fees from Sunovion, personal fees from Takeda, outside the submitted work. BTB reports personal fees from AstraZeneca, personal fees from Lundbeck, personal fees from Pfizer, personal fees from Takeda, personal fees from Servier, personal fees from Bristol Myers Squibb, personal fees from Otsuka, personal fees from LivaNova, personal fees from Janssen-Cilag, outside the submitted work. PB reports personal fees from Allergan, personal fees from Eisai, personal fees from Janssen, personal fees from Lundbeck, personal fees from Otsuka, personal fees from Pfizer, personal fees from Pierre Fabre M\u00e9dicaments, personal fees from Takeda, outside the submitted work; and Expert testimony was provided on behalf of Allergan, Bristol Myers Squibb and Otsuka. AJC reports personal fees from Lundbeck, personal fees from Janssen, personal fees from Livanova, personal fees from Allergan, personal fees from NICE, grants from Medical Research Council (UK), grants from Wellcome Trust (UK), grants from National Institute for Health Research (UK), grants from Protexin Probiotics International Ltd., outside the submitted work. PJC has a patent for Ebselen in treatment-resistant depression pending. TGD has nothing to disclose. AF reports grants and personal fees from Angelini, grants and personal fees from Apsen, grants and personal fees from Boheringer Ingelheim, grants and personal fees from Daiichi Sankyo, grants and personal fees from Doc Generici, grants and personal fees from Glaxo Smith Kline, grants and personal fees from Italfarmaco, grants and personal fees from Lundbeck, grants and personal fees from Janssen, grants and personal fees from Mylan, grants and personal fees from Neuraxpharm, grants and personal fees from Otsuka, grants and personal fees from Pfizer, grants and personal fees from Recordati, grants and personal fees from Sanofi Aventis, grants and personal fees from Sunovion, grants and personal fees from Vifor, outside the submitted work. INF has nothing to disclose. UH reports personal fees from Janssen, personal fees from Servier, personal fees from Medice, outside the submitted work. ADK reports grants and personal fees from Janssen Pharmaceuticals, grants from Axsome Pharmaceutics, grants from Reveal Biosensors, grants from The Ray and Dagmar Dolby Family Fund, grants from National Institutes of Health, personal fees from Adare, personal fees from Axsome Therapeutics, personal fees from Big Health, personal fees from Eisai, personal fees from Evecxia, personal fees from Ferring Pharmaceuticals, personal fees from Galderma, personal fees from Harmony Biosciences, personal fees from Idorsia, personal fees from Jazz Pharmaceuticals, personal fees from Millenium Pharmaceuticals, personal fees from Merck, personal fees from Neurocrine Biosciences, personal fees from Neurawell, personal fees from Pernix, personal fees from Otsuka Pharmaceuticals, personal fees from Sage, personal fees from Takeda, personal fees from Harmony, outside the submitted work. ML has nothing to disclose. RHM-W reports personal fees from Janssen-Cilag, personal fees from LivaNova, personal fees from Lundbeck, personal fees from P1 Vital Ltd, personal fees from Pfizer, personal fees from Sage Therapeutics, personal fees from Sunovian, non-financial support from MagStim, grants from AstraZeneca, personal fees from My Tomorrows, personal fees from OCM Communications s.n.c, personal fees from Syntropharma, outside the submitted work. RSM reports grants from CIHR, grants from GACD, grants from Chinese National Natural Research Foundation, personal fees from Lundbeck, personal fees from Janssen, personal fees from Purdue, personal fees from Pfizer, personal fees from Otsuka, personal fees from Allergan, personal fees from Takeda, personal fees from Neurocrine, personal fees from Sunovion, personal fees from Eisai, personal fees from Minerva, personal fees from Intra-Cellular, personal fees from Abbvie, other from AltMed, outside the submitted work. AM-L reports personal fees from Agence Nationale de la Recherche, personal fees from American Association for the Advancement of Science, personal fees from Brain Mind Institute, personal fees from Brainsway, personal fees from Catania International Summer School of Neuroscience (CISSN), personal fees from Daimler und Benz Stiftung, personal fees from Fondation FondaMental, personal fees from Janssen-Cilag GmbH, personal fees from Lundbeck A\/S, personal fees from Lundbeck Int. Neuroscience Foundation, personal fees from MedinCell, personal fees from Sage Therapeutics, personal fees from Techspert.io, personal fees from Thieme Verlag, personal fees from von Behring R\u00f6ntgen Stiftung, personal fees from BAG Psychiatrie Oberbayern, personal fees from Biotest AG, personal fees from Forum Werkstatt Karlsruhe, personal fees from International Society of Psychiatric Genetics, personal fees from Brentwood, personal fees from Klinik f\u00fcr Psychiatrie und Psychotherapie Ingolstadt, personal fees from Lundbeck SAS France, personal fees from med Update GmbH, personal fees from Merz-Stiftung, personal fees from Siemens Healthineers, outside the submitted work. AHM reports personal fees from Boehringer Ingelheim, outside the submitted work. CBN reports grants from National Institutes of Health (NIH), personal fees from ANeuroTech (division of Anima BV), personal fees from Taisho Pharmaceutical, Inc, personal fees from Takeda, personal fees from Signant Health, personal fees from Sunovion Pharmaceuticals, Inc, personal fees from Janssen Research & Development LLC, personal fees from Magstim, Inc, personal fees from Navitor Pharmaceuticals, Inc, personal fees from Intra-Cellular Therapies, Inc, personal fees and other from EMA Wellness, personal fees from Acadia Pharmaceuticals, personal fees from Axsome, personal fees from Sage, personal fees from BioXcel Therapeutics, personal fees from Silo Pharma, personal fees from XW Pharma, personal fees from Neuritek, personal fees from Engrail Therapeutics, personal fees from Brain and Behavior Research Foundation (BBRF), personal fees and other from Anxiety and Depression Association of America (ADAA), personal fees from Skyland Trail, personal fees from Signant Health, personal fees from Laureate Institute for Brain Research (LIBR), Inc, personal fees from Magnolia CNS, other from Gratitude America, other from Xhale Smart, Inc, other from Xhale, other from Seattle Genetics, other from Antares, other from BI Gen Holdings, Inc, other from Corcept Therapeutics Pharmaceuticals Company, from null, outside the submitted work; In addition, CBN has a patent Method and devices for transdermal delivery of lithium (US 6, 375, 990B1) issued, and a patent Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7, 148, 027B2) issued. CN reports personal fees from Johnson\/Janssen-Cilag, outside the submitted work. DN reports personal fees from British National Formulary, personal fees from Ranvier, personal fees from Opiant, personal fees from COMPASS Pathways, personal fees from AWAKN, personal fees from Psyched Wellness, personal fees from Lundbeck, personal fees from BMS\/Otsuka, personal fees from Janssen, personal fees from Takeda, grants from Wellcome Trust, MRC, other from P1vital, other from Awakn, other from Psyched Wellness, other from Equasy Enterprises, other from Alcarelle, outside the submitted work; and Expert witness related to psychotropic drugs in several legal cases. Edited\/written more than 34 books, some purchased by pharmaceutical companies. SPa reports grants from R21 NIMH (R21DA042271-01), outside the submitted work. LP reports personal fees from University of Modena and Reggio Emilia, personal fees from University of Miami, personal fees from EDRA-LSWR Publishing Company, personal fees from Inpeco SA Total Lab Automation Company, personal fees from VeraSci, Durham, USA, personal fees from AbbVie USA, personal fees from Acadia USA, personal fees from BCG Switzerland, personal fees from Boehringer Ingelheim International GmbH, personal fees from Compass Pathways, personal fees from Ferrer Spain, personal fees from Gedeon-Richter, Hungary, personal fees from Johnson & Johnson USA, personal fees from NeuroCog Trials USA, personal fees from Novartis-Gene Therapies, Switzerland, personal fees from Otsuka USA, personal fees from Pfizer Global USA, personal fees from PharmaMar Spain, personal fees from Relmada USA, personal fees from Takeda USA, personal fees from Vifor Switzerland, outside the submitted work. BWJHP reports grants from Boehringer Ingelheim, grants from Janssen Research, outside the submitted work. AFS reports personal fees from Axsome, personal fees and other from Delpor, personal fees and other from NeuraWell, personal fees from ANeuroTech, personal fees from Signant, personal fees from Otsuka, personal fees from EMA Wellness, personal fees and other from Owl Insights, personal fees and other from Alto, personal fees and other from Verso, personal fees from Compass, personal fees from Janssen, personal fees from Tris, personal fees from Schwabe, personal fees from Boehringer Ingelheim, personal fees from McKinsey, other from Corcept, other from Merck, other from Seattle Genetics, other from XHale, other from Intersect, other from Epiodyne, outside the submitted work. RCS reports grants from Agency for Healthcare Research and Quality, grants and personal fees from Allergan, grants from Assurex Health, grants from Avanir Pharmaceuticals, grants and personal fees from Cerecor, Inc, personal fees from Clintara LLC, grants from Genomind, grants and personal fees from Janssen Pharmaceutica, personal fees from Medtronic, Inc., grants from Novartis, Inc., personal fees from Pfizer, Inc., grants and personal fees from Otsuka Pharmaceuticals, grants and personal fees from Acadia Pharmaceuticals, grants from Alkermes, PLC, grants and personal fees from Takeda Pharmaceuticals, grants from NeuroRx Inc., outside the submitted work. LNY reports personal fees from Alkermes, grants and personal fees from Allergan, personal fees from CANMAT, grants and personal fees from CIHR, grants and personal fees from Dainippon Sumitomo, grants and personal fees from Intracellular Therapies, grants and personal fees from Lundbeck, personal fees from Merck, personal fees from Otsuka, personal fees from Sanofi, personal fees from Sunovion, outside the submitted work. AHY reports personal fees from King\u2019s College London, personal fees from Sumitomo Dainippon Pharma, grants from MRC (UK), grants from Wellcome Trust (UK), grants from NIHR (UK), outside the submitted work; and Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: \u201cAn Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.\u201d Principal Investigator on \u201cThe Effects of Psilocybin on Cognitive Function in Healthy Participants.\u201d Principal Investigator on \u201cThe Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)\u201d. RZ reports personal fees from The London Depression Institute, personal fees from Lundbeck, personal fees from Janssen, personal fees from Depsee Ltd, personal fees from Scients Institute, Palo Alto, outside the submitted work; and Co-Investigator on a LivaNova Funded observational study of Vagus Nerve Stimulation for Depression. Collaborated with EMIS PLC for a study. Affiliated with the D\u2019Or Institute of Research and Education, Rio de Janeiro. GA reports personal fees from BfArM (Federal Institute for Drugs and Medical Devices), personal fees from EMA (No money, honoraria or other kind of compensation paid for services rendered. Only travel and accommodation expenses are covered together with travel allowance from EMA), personal fees from University of Thessaly (Greece) and University of Nicosia (Cyprus) (Honoraria for lectures in Postgraduate Program) outside the submitted work. FB-D has nothing to disclose. CF reports personal fees and other from GSK, outside the submitted work. MH reports personal fees from BfArM, personal fees from EMA (No money, honoraria or other kind of compensation paid for services rendered. Only travel and accommodation expenses are covered together with travel allowance from EMA), personal fees from Forum-Institut, outside the submitted work. TL reports personal fees from Massachusetts General Hospital Clinical Trials Network and Institute, personal fees from Acadia, personal fees from Alairion, personal fees from Antares, personal fees from Aptinyx, personal fees from Arbor, personal fees from AxsomeBetterLife, personal fees from Biohaven, personal fees from Cadent, personal fees from Cereval, personal fees from Cingulate, personal fees from Corteyxme, personal fees from Eleusis, personal fees from Emerald Lake Safety, personal fees from Greenwich, personal fees from Harmony, personal fees from Janssen, personal fees from Karuna, personal fees from KemPharm, personal fees from LB Pharmaceuticals, personal fees from LevoTx, personal fees from MAPS, personal fees from Merck, personal fees from Minerva, personal fees from Neurocrine Biosciences, personal fees from Neuronetics, personal fees from Noema, personal fees from Novartis Pharma AG, personal fees from Novartis US, personal fees from Praxis Biosciences, personal fees from Promentis, personal fees from Tonix, personal fees from Vallon, personal fees from Waypoint, outside the submitted work. F-LM reports personal fees from HUS Helsinki University Hospital, non-financial support from European Patients\u2019 Forum, outside the submitted work. KS has nothing to disclose. AT has nothing to disclose. GA-H reports grants from European Commission (IMI2 853966), during the conduct of the study; grants from European Union\u2019s Horizon 2020 Research and Innovation Program (grant agreement no.728018), outside the submitted work. FB reports grants from European Commission (IMI2 853966), during the conduct of the study. LC-G reports grants from European Commission (IMI2 853966), during the conduct of the study. WRC reports grants from European Commission (IMI2 853966), during the conduct of the study. HDS reports non-financial support from EU-PEARL Project, during the conduct of the study; personal fees from Janssen, outside the submitted work. SMG reports grants from European Commission (IMI2 853966), during the conduct of the study; personal fees from Almirall SA, personal fees from Celgene, personal fees from Forum fu\u0308r Medizinische Fortbildung (FomF), personal fees from Mylan GmbH, non-financial support from GAIA Group, grants from Deutsche Forschungsgemeinschaft, grants from German Federal Ministry of Health, grants from National Multiple Sclerosis Society, outside the submitted work. WJGH reports grants from European Commission (IMI2 853966), during the conduct of the study. VJM reports non-financial support from EU-PEARL Project, during the conduct of the study; personal fees from Novartis Pharma AG, outside the submitted work. EMa reports grants from European Commission (IMI2 853966), during the conduct of the study; personal fees from Lundbeck, personal fees from Janssen-Cilag, outside the submitted work. JM reports non-financial support from EU-PEARL Project, during the conduct of the study; personal fees from Janssen, outside the submitted work. EMe reports grants from European Commission (IMI2 853966), during the conduct of the study. CO reports grants from European Commission (IMI2 853966), during the conduct of the study; personal fees from Ferring, personal fees from Janssen, personal fees from Lundbeck, personal fees from SAGE Therapeutics, personal fees from Fortbildungskolleg, personal fees from Limes Klinikgruppe, personal fees from Medical Tribune, grants from German Research Foundation (OT 209\/7-3; 14-1, EXC 2049), grants from German Federal Ministry of Education and Research (KS2017-067), grants from Berlin Institute of Health (B3010350), outside the submitted work. GP-F reports grants from European Commission (IMI2 853966), during the conduct of the study. SPo reports grants from European Commission (IMI2 853966), during the conduct of the study. MES reports non-financial support from EU-PEARL Project, during the conduct of the study; personal fees from Janssen Pharmaceutica NV, other from Johnson & Johnson, other from Novartis Inc., outside the submitted work. EvdK reports grants from European Commission (IMI2 853966), during the conduct of the study. KW reports non-financial support from EU-PEARL Project, during the conduct of the study; personal fees from Janssen R&D LLC, other from Johnson & Johnson, outside the submitted work. YF reports non-financial support from EU-PEARL Project, during the conduct of the study; personal fees from Novartis Pharma AG, outside the submitted work. JAR-Q reports grants from European Commission (IMI2 853966), during the conduct of the study; personal fees and non-financial support from Eli-Lilly, personal fees and non-financial support from Janssen-Cilag, personal fees from Novartis, personal fees and non-financial support from Shire, personal fees and non-financial support from Takeda, personal fees from Bial, personal fees and non-financial support from Shionogi, personal fees from Lundbeck, personal fees from Almirall, personal fees from Braingaze, personal fees from Sincrolab, personal fees and non-financial support from Medice, personal fees and non-financial support from Rubi\u00f3, personal fees from Raffo, personal fees from Actelion, personal fees from Ferrer, personal fees from Oryzon, personal fees from Roche, personal fees from Psious, outside the submitted work. AJS reports non-financial support from EU-PEARL Project, during the conduct of the study; personal fees from Johnson & Johnson, outside the submitted work (employee and own stock in the company). CMP reports grants from European Commission (IMI2 853966), during the conduct of the study. Additional funding has been provided by UK National Institute of Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Trust and King\u2019s College London. He is also funded by a NIHR Senior Investigator Award. He has received research or consultation funding from Johnson & Johnson and Boehringer Ingelheim, as well as research funding from the Medical Research Council (UK) and the Wellcome Trust for research on depression and inflammation as part of two large consortia that also include Johnson & Johnson, GSK and Lundbeck.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}